Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
HORIZON-Lung
A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer
- NCT04818333 ↗
- Unknown
- Jiangsu HengRui Medicine Co., Ltd.
- Focused
We haven't built an HCP commentary report on HORIZON-Lung (SHR-A1811 in Advanced Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HORIZON-Lung so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression , Amplification, or Mutation
- Phase
- Phase 1/Phase 2
- Status
- Unknown
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- SHR-A1811
- Arms
- SHR-A1811 · Experimental
- Enrollment
- 157
- Primary outcomes
- Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811
- Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811
- Phase1: Maximum tolerated dose (MTD)
- Phase 1: Recommended Phase 2 dose (RP2D)
- Phase2:ObjectiveResponse Rate (ORR)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Start
- Apr 23, 2021
- Primary completion
- Jun 2025 (estimated)
- Results posted
- No
- Registry record
- NCT04818333 · updated Jun 13, 2024
Publications
linked from the registry- Li Z, Wang Y, Sun Y, Wang L, Li X, Sun L, He Z, Yang H, Wang Y, Wang Q, Song Z, Hong W, Wang Y, Xia G, Yu Y, Peng M, Song Y, Wang D, Meng R, Fang J, Luo Y, Liang W, Hu S, Wang Z, Song K, Li Y, Yang L, Shi W, Lu S. Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol. 2025 Apr;26(4):437-446. doi: 10.1016/S1470-2045(25)00012-9. Epub 2025 Feb 25. PubMed 40020696
- Li Z, Song Z, Hong W, Yang N, Wang Y, Jian H, Liang Z, Hu S, Peng M, Yu Y, Wang Y, Jiao Z, Zhao K, Song K, Li Y, Shi W, Lu S. SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study. Signal Transduct Target Ther. 2024 Jul 15;9(1):182. doi: 10.1038/s41392-024-01897-y. PubMed 39004647